Lupin Limited

Lupin Limited is an Indian multinational pharmaceutical company based in Mumbai, Maharashtra, India. It was established in 1968 by Dr. Desh Bandhu Gupta. It is one of the largest generic pharmaceutical companies by revenue globally. The company’s key focus areas include paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.  Lupin employs 20,000 + members in 11 countries across six continents, enabling safe and reliable delivery of medicines to their patients across 100 + countries.

With an expansive portfolio of products, they deliver thousands of different products to patients across 100 countries. Millions of people around the world take a Lupin medicine daily. In the US, they are the third-largest generic pharmaceutical company by prescription. In India, they rank among the top five pharma brands. Three of their brands rank among the top 100 brands in the Indian pharmaceutical market (IPM). Lupin is the largest providers of anti-TB. API to over several leading global institutions. they enjoy substantial market share in therapies such as cardiovascular, respiratory, diabetes, neurology, gastrointestinal and women’s health.

Lupin CSR programme areas and interventions focuses on mainly these six heads: Economic Development Programme, Social Development Programme, Rural infrastructure Development Programme, Natural Resource Management Programme, Disaster response and management programme, Deeper and sustainable projects.

Covid-19 Response

The Lupin Foundation has rushed to their rescue by providing cooked food, food grains, medical supplies, shelter and other support. ‘LIBERATE’, a helpline that offered medical advice and guidance, was launched for the benefit of Lupin employees. Medical experts handled queries related to health issues around COVID-19. ‘SAMVAD’ was initiated to connect all employees across the world with their leadership teams. This programme facilitated seamless coordination on various customer-centric and employee-centric initiatives by Lupin. The company launched Covihalt (Favipiravir) in India for mild to moderate cases of COVID-19 infection. As the largest supplier of Azithromycin in the US, they also launched Albuterol, a key rescue inhalation product, in the US.

Their shareholding pattern consists of Promoters and Promoter Group having 46.84% of shares, Public having 12.47% shares, Government having 0.28% following by FII’s having 18.60% shares and DII’s with 21.81% shares.